[A pyrazolinone derivative with potential antimetastatic activities. Nafazatrom, originally developed as an antithrombotic agent, inhibits the key prostaglandin catabolic enzyme, 15-hydroxyprostaglandin dehydrogenase, thereby prolonging the biological half-life of prostacyclin (prostaglandin I2; PGI2) and preventing intravascular coagulation. This agent also serves as a reducing cofactor with the hydroperoxidase moiety of cyclooxygenase and accelerates the conversion of arachidonic acid into precursors of PGI2. Elevated level of PGI2 prevents aggregation of platelets and subsequently, decreases the formation of tumor cell-platelet aggregates as well as their sequestration in blood vessels, which is an important initiating step in the development of metastasis. ( NCI )]
UMLS (NCI) C0053025 - Organic Chemical
- Pharmacologic Substance
home 
Armenian-English 
top